Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
A new antibody-drug conjugate combo is shaking up first-line lung cancer treatment. In the phase 3 OptiTROP-Lung06 trial, sacituzumab tirumotecan (sac-TMT) plus pembrolizumab nearly tripled median progression-free survival compared to standard chemoimmunotherapy in patients with PD-L1–negative advanced nonsquamous NSCLC. The combo also showed a more favorable safety profile, with fewer severe side effects.
A new treatment combination is showing impressive results for one of the trickiest subgroups in lung cancer. In the phase 3 OptiTROP-Lung06 trial, the antibody-drug conjugate sacituzumab tirumotecan (sac-TMT) paired with pembrolizumab nearly tripled median progression-free survival (PFS) compared to standard platinum-based chemoimmunotherapy in patients with PD-L1–negative advanced nonsquamous non–small cell lung cancer (NSCLC) lacking EGFR or ALK alterations — a group that historically has limited options.
The results, presented at the 2026 ESMO Congress, are particularly notable because PD-L1–negative tumors typically don't respond well to immunotherapy alone, making this combination a potential game-changer for first-line treatment.
By the Numbers:
Why it matters: PD-L1–negative NSCLC patients have long been underserved by immunotherapy-based regimens. This data suggests sac-TMT plus pembrolizumab could redefine the standard of care for this population — offering both longer disease control and a more tolerable side effect profile than current chemotherapy-based approaches.
